Responses
Oncolytic and local immunotherapy
Original research
Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.